Notably, in these latter GBM patients, various microRNAs (miR-142-3p, miR-181d, miR-221/222, miR-370-3p, and miR-603) acting as epigenetic negative regulators of MGMT expression and/or functionality are able to increase sensitivity to TMZ in vitro as well as in vivo [35]. The gene discussed is MGMT; the disease is glioblastoma.